STAT+: Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open
STAT
MARCH 14, 2024
WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT. Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law , the Food and Drug
Let's personalize your content